Promising drug cocktail aims to stall aggressive lung cancer

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, with regular scans to track tumor changes. The goal is to see if this maintenance therapy keeps the cancer from progressing after initial chemotherapy.